Market Overview:
The global pseudorabies virus vaccine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for safe and efficacious vaccines against pseudorabies virus infections. In addition, the growing awareness about animal health and zoonotic diseases is also contributing to the growth of this market. The global pseudorabies virus vaccine market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into inactivated vaccine, naturally deficient attenuated vaccine, genetic engineering vaccine, and others. The inactivated vaccines are those that have been killed with heat or chemicals and are used for immunization against diseases such as rabies or hepatitis A & B viruses. The naturally deficient attenuated vaccines are those that have been weakened through natural processes such as passage through animals or insects; these vaccines offer protection against diseases such as yellow fever virus infection. The genetic engineering vaccines are made by altering viral genes using recombinant DNA technology; they offer protection against a variety of viral infections including pseudorabies virus infection. On the basis of application, it can be classified into government tender Vaccine Sales Market . Geographically speaking ,the global Pseudorabies Virus Vaccine Market has been segmented into North America Latin America Europe Asia Pacific Middle East Africa With respect to each region ,the respective submarkets are analyzed in detail .
Product Definition:
Pseudorabies virus vaccine is used to prevent pseudorabies, a viral disease which can cause severe illness in pigs. Pseudorabies virus vaccine is important because it can help protect pigs from this serious disease.
Inactivated Vaccine:
Inactivated vaccines are those that have been rendered inert by heat treatment at a specific temperature. The most commonly used inactivated vaccine is formalin-fixed, paraffin-embedded (FFPE) which is generally used for the prevention of rabies. Other inactivating agents include formaldehyde and glutaraldehyde.
Naturally Deficient Attenuated Vaccine:
The naturally deficient attenuated vaccine (NDAV) is a vaccine developed to prevent rabies. It consists of weakened forms of the virus that induce an immune response but do not cause disease. The NDAV was first used in human trials in France in 1995 and 1996, on 3 occasions; all attempts were failures.
Application Insights:
On the basis of application, the global pseudorabies virus vaccine market is segmented into government tender, market sales, and others. The government tender segment held a major share in 2017 owing to high usage rates for disease control and eradication purposes in several countries. This is also supported by increasing R&D investments for developing new vaccines against pseudorabies virus.
The other applications include use of naturally deficient attenuated vaccines or genetic engineered vaccines among others.
Regional Analysis:
North America was the largest regional market in 2017 owing to high R&D investments and presence of key manufacturers. The region is expected to maintain its dominance over the forecast period due to increasing awareness about vaccination programs, availability of effective treatment methods, and rising incidence rate of PRV in U.S.
Asia Pacific is anticipated to be the fastest-growing regional market from 2018 to 2030 on account of increasing number of vaccine development projects by several governments as well as private companies for preventing disease outbreak & maintaining high immunity among livestock population across countries such as India, China, Indonesia & Japan etc. In addition, growing awareness about diseases and their treatment methods will drive demand further over the forecast period.
Growth Factors:
- Increasing demand for livestock products: The global population is increasing at a rapid pace and with this the demand for livestock products is also increasing. This will create a need for more Pseudorabies Virus Vaccine which in turn will drive the growth of the market.
- Rising awareness about animal health: There is an increase in awareness among people about animal health and its importance. This has led to an increase in the number of people who are willing to invest in Pseudorabies Virus Vaccine, thereby driving market growth.
- Technological advancements: The Pseudorabies Virus Vaccine market is witnessing significant advancements due to which new and innovative products are being launched in the market on a regular basis. This is helping fuel market growth as well as innovation within the industry players themselves . 4) Growing demand from emerging markets: A large number of emerging markets such as China, India, Brazil etc., are witnessing high economic growth rates which is resulting in an increase in disposable income levels among their populations As a result, there is growing demand for various types of goods and services including Pseudorabies Virus Vaccines thereby fuelling itsgrowth prospects 5) Increasein trade activities: There has been a significant risein international trade activities overthe past few years owingto globalizationand liberalizationof economies acrossthe worldThis has led tobetter connectivityamong different parts ofthe worldand increasedtrade opportunitiesfor companiesinvolvedinthepseudorabiesvirusvacc
Scope Of The Report
Report Attributes
Report Details
Report Title
Pseudorabies Virus Vaccine Market Research Report
By Type
Inactivated Vaccine, Naturally Deficient Attenuated Vaccine, Genetic Engineering Vaccine,
By Application
Government Tender, Market Sales,
By Companies
Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd., CHINA ANIMAL HUSBANDRY INDUSTRY, Sichuan Huashen, Haley, Tianbang, Dabei Nong, Harvey, Preh Bio, Jiangsu Nannong High-Tech Co., Guangxi Liyuan Biological Co., Ltd., Jilin Zhengye Bioengineering Group, Jilin Heyuan Biological Engineering Co., Ltd., Huapai Biological Engineering Group Co., Ltd., Beijing Xinde Weite Technology Co., Ltd., Beijing Veterinary Biopharmaceutical Factory, Qilu Animal Health Products Co., Ltd., Shanxi Longkel Bio-Pharmaceutical Co., Ltd., Yunnan Biopharmaceutical Co., Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd., Liaoning Yikang Biological Co., Ltd., Shanghui Huahong Biological Engineering Co., Ltd., Sichuan Hailinge Biological Pharmaceutical Co., Ltd., Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Pseudorabies Virus Vaccine Market Report Segments:
The global Pseudorabies Virus Vaccine market is segmented on the basis of:
Types
Inactivated Vaccine, Naturally Deficient Attenuated Vaccine, Genetic Engineering Vaccine,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Government Tender, Market Sales,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Merial Limited
- Boehringer Ingelheim Animal Health (USA) Co., Ltd.
- Zoetis
- Hipra
- Anhui Divinity Biological Products
- Wuhan Keqian Biological Co., Ltd.
- China Biotechnology Co., Ltd.
- CHINA ANIMAL HUSBANDRY INDUSTRY
- Sichuan Huashen
- Haley
- Tianbang
- Dabei Nong
- Harvey
- Preh Bio
- Jiangsu Nannong High-Tech Co.
- Guangxi Liyuan Biological Co., Ltd.
- Jilin Zhengye Bioengineering Group
- Jilin Heyuan Biological Engineering Co., Ltd.
- Huapai Biological Engineering Group Co., Ltd.
- Beijing Xinde Weite Technology Co., Ltd.
- Beijing Veterinary Biopharmaceutical Factory
- Qilu Animal Health Products Co., Ltd.
- Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
- Yunnan Biopharmaceutical Co.
- Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
- Liaoning Yikang Biological Co., Ltd.
- Shanghui Huahong Biological Engineering Co., Ltd.
- Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
- Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
Highlights of The Pseudorabies Virus Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Inactivated Vaccine
- Naturally Deficient Attenuated Vaccine
- Genetic Engineering Vaccine
- By Application:
- Government Tender
- Market Sales
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pseudorabies Virus Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pseudorabies virus vaccine is a vaccine that helps protect people from pseudorabies, a viral disease that can cause serious health problems in infants and young children. Pseudorabies virus is spread through contact with the saliva or mucus of an infected person, typically during close contact with the face, mouth, or anus. The vaccine helps prevent infection by protecting against three different types of pseudorabies viruses.
Some of the major companies in the pseudorabies virus vaccine market are Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd., CHINA ANIMAL HUSBANDRY INDUSTRY, Sichuan Huashen, Haley, Tianbang, Dabei Nong, Harvey, Preh Bio, Jiangsu Nannong High-Tech Co., Guangxi Liyuan Biological Co., Ltd., Jilin Zhengye Bioengineering Group, Jilin Heyuan Biological Engineering Co., Ltd., Huapai Biological Engineering Group Co., Ltd., Beijing Xinde Weite Technology Co., Ltd., Beijing Veterinary Biopharmaceutical Factory, Qilu Animal Health Products Co., Ltd., Shanxi Longkel Bio-Pharmaceutical Co., Ltd., Yunnan Biopharmaceutical Co., Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd., Liaoning Yikang Biological Co., Ltd., Shanghui Huahong Biological Engineering Co., Ltd., Sichuan Hailinge Biological Pharmaceutical Co., Ltd., Guangdong Yongshun Biological Pharmaceutical Co., Ltd..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pseudorabies Virus Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pseudorabies Virus Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pseudorabies Virus Vaccine Market - Supply Chain
4.5. Global Pseudorabies Virus Vaccine Market Forecast
4.5.1. Pseudorabies Virus Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pseudorabies Virus Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pseudorabies Virus Vaccine Market Absolute $ Opportunity
5. Global Pseudorabies Virus Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pseudorabies Virus Vaccine Market Size and Volume Forecast by Type
5.3.1. Inactivated Vaccine
5.3.2. Naturally Deficient Attenuated Vaccine
5.3.3. Genetic Engineering Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pseudorabies Virus Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pseudorabies Virus Vaccine Market Size and Volume Forecast by Application
6.3.1. Government Tender
6.3.2. Market Sales
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pseudorabies Virus Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pseudorabies Virus Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pseudorabies Virus Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pseudorabies Virus Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pseudorabies Virus Vaccine Demand Share Forecast, 2019-2026
9. North America Pseudorabies Virus Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pseudorabies Virus Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pseudorabies Virus Vaccine Market Size and Volume Forecast by Application
9.4.1. Government Tender
9.4.2. Market Sales
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pseudorabies Virus Vaccine Market Size and Volume Forecast by Type
9.7.1. Inactivated Vaccine
9.7.2. Naturally Deficient Attenuated Vaccine
9.7.3. Genetic Engineering Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pseudorabies Virus Vaccine Demand Share Forecast, 2019-2026
10. Latin America Pseudorabies Virus Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pseudorabies Virus Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pseudorabies Virus Vaccine Market Size and Volume Forecast by Application
10.4.1. Government Tender
10.4.2. Market Sales
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pseudorabies Virus Vaccine Market Size and Volume Forecast by Type
10.7.1. Inactivated Vaccine
10.7.2. Naturally Deficient Attenuated Vaccine
10.7.3. Genetic Engineering Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pseudorabies Virus Vaccine Demand Share Forecast, 2019-2026
11. Europe Pseudorabies Virus Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pseudorabies Virus Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pseudorabies Virus Vaccine Market Size and Volume Forecast by Application
11.4.1. Government Tender
11.4.2. Market Sales
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pseudorabies Virus Vaccine Market Size and Volume Forecast by Type
11.7.1. Inactivated Vaccine
11.7.2. Naturally Deficient Attenuated Vaccine
11.7.3. Genetic Engineering Vaccine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractivness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pseudorabies Virus Vaccine Demand Share, 2019-2026
12. Asia Pacific Pseudorabies Virus Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pseudorabies Virus Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pseudorabies Virus Vaccine Market Size and Volume Forecast by Application
12.4.1. Government Tender
12.4.2. Market Sales
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pseudorabies Virus Vaccine Market Size and Volume Forecast by Type
12.7.1. Inactivated Vaccine
12.7.2. Naturally Deficient Attenuated Vaccine
12.7.3. Genetic Engineering Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pseudorabies Virus Vaccine Demand Share, 2019-2026
13. Middle East & Africa Pseudorabies Virus Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pseudorabies Virus Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pseudorabies Virus Vaccine Market Size and Volume Forecast by Application
13.4.1. Government Tender
13.4.2. Market Sales
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pseudorabies Virus Vaccine Market Size and Volume Forecast by Type
13.7.1. Inactivated Vaccine
13.7.2. Naturally Deficient Attenuated Vaccine
13.7.3. Genetic Engineering Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pseudorabies Virus Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pseudorabies Virus Vaccine Market: Market Share Analysis
14.2. Pseudorabies Virus Vaccine Distributors and Customers
14.3. Pseudorabies Virus Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merial Limited
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Boehringer Ingelheim Animal Health (USA) Co., Ltd.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Zoetis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Hipra
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Anhui Divinity Biological Products
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Wuhan Keqian Biological Co., Ltd.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. China Biotechnology Co., Ltd.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. CHINA ANIMAL HUSBANDRY INDUSTRY
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sichuan Huashen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Haley
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Tianbang
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Dabei Nong
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Harvey
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Preh Bio
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Jiangsu Nannong High-Tech Co.
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Guangxi Liyuan Biological Co., Ltd.
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Jilin Zhengye Bioengineering Group
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Jilin Heyuan Biological Engineering Co., Ltd.
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Huapai Biological Engineering Group Co., Ltd.
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
